The left-brain right-brain divide is bunk. And a Baltimore graduate program is celebrating that.
“We have people who have worked in the military, nonprofits, startups, started their own company, worked for huge corporations,” said Julie Buisson, a graduate assistant with the Design Leadership MBA/MA program from Johns Hopkins University’s Carey Business School and the Maryland Institute College of Art.
To say there has been change in the health care industry is an understatement. Sweeping national reform and a major shift in the way Maryland hospitals are paid are dramatically overhauling how business is done. Regardless of where you stand on Obamacare and Maryland’s Medicare waiver, you can’t ignore that reform and technology are creating lots of opportunities for innovation in a field that for too long accepted the status quo.
That’s why the Baltimore Business Journal is recognizing those innovators who are creating new health care products and strategies — whether it’s a medical device, new drug, software or a system to improve safety at the region’s hospitals. We’re looking for people and companies that are doing amazing work developing ways to make health care even more accessible, efficient and effective.
The winners of the BBJ’s 2014 Health Care Innovators will be judged for strong ideas, results and vision in several categories. Tell us why you think an innovative technology, strategy or product should be honored. How has it improved the way business is done or health care is delivered? The winners will be featured in the Nov. 7 Baltimore Business Journal and will be recognized at a special event. The BBJ will convene a panel of judges to determine the winners in the following categories:
The 2014 International Biotech Summit Committee invite BioHealth Innovation (BHI) and Montgomery County to attend the three co-located international conferences that will be held on Sep 9 -12 in Shenzhen, China:
- 2014 International Biotech Summit (September 10, 2014);
- The 9th International Conference on Genomics (ICG-9) (September 11th-12th, 2014);
- Shenzhen International Biotech & Health Industry Expo 2014 (SIBHIE, September 10th-12th, 2014).
Ms. Lily Qi, Director of Special Projects for Montgomery County Executive Office who was involved in establishing BHI and a native of Shanghai, is going to speak on behalf of the County and BHI for the forum, “Innovation in Policy and Regulation for Advancing Healthcare Industry.” BHI and the County are also invited as an exhibitor for the SIBHIE Expo.
Senior Director, External Partnerships & Collaborations, MedImmune
Jarrod Borkat is a 15-year veteran in the biopharmaceutical industry. He joined MedImmune in 2010, where he currently serves as Senior Director/Head, Global External Partnerships & Collaborations. In this role he is responsible for establishing and overseeing global strategic collaborations with universities, non-profit organizations and government entities, across all the therapeutic areas relevant to MedImmune. His team led the creation of several multi-million dollar collaborations, including one with Johns Hopkins University and one with University of Maryland. Prior to this role, Jarrod led the Portfolio Strategy & Management function for MedImmune, helping the organization optimize its R&D portfolio. Before joining MedImmune, Jarrod worked at Boehringer Ingelheim (BI) Pharmaceuticals, Inc. for 11 years, rising through the ranks in the sales and commercial organization. During his time at BI, he spent two years in Germany, working at their corporate headquarters, leading the global commercial strategy for their CNS franchise. His last position prior to leaving BI was Director of U.S. Marketing, HIV. Jarrod has won multiple awards throughout his career, including being recognized as an industry “Top 25 Direct-to-Consumer Marketer of the Year” in 2007. He is also active in several industry organizations and has served on industry-related panels. In addition to his professional accomplishments, Jarrod serves on the Kentlands Board of Trustees and the Kentlands Community Foundation Board. He also ran a marathon on all 7 continents with his father, making them the first father/son duo to have accomplished this challenging endeavor. Jarrod earned an M.B.A. from Kennesaw State University, with concentrations in finance and marketing, and earned a B.S. in Biology from the University of Georgia.
– Representatives from Sigma-Tau Pharmaceuticals Inc., Alexandria Real Estate Equities, Inc., and Deloitte Consulting LLP Take New Board Seats –
– Charles Morton Becomes New Venable LLP Representative on Board while Mike Baader Stays on as Board Member (Now as Greenspring Associates Representative) –
ROCKVILLE AND BALTIMORE, MARYLAND, August 11, 2014 – BioHealth Innovation, Inc. (BHI) announced today the appointment of four new members to its Board of Directors. Dave Lemus, Chief Executive Officer, Sigma-Tau Pharmaceuticals Inc.; Joel S. Marcus, Chairman, Chief Executive Officer, and Founder, Alexandria Real Estate Equities, Inc. (Alexandria Venture Investments); and Beth Meagher, Principal, Deloitte Consulting LLP, have joined the BHI Board of Directors, effective August 7, 2014, based upon their organizations’ newly committed support of BHI. Charles “Chuck” Morton now represents Venable LLP on the Board, as another new Board member, while Mike Baader, formerly with Venable, will continue to hold a seat on the Board, but now as a representative of Greenspring Associates. Cynthia L. Collins, CEO, Clarient, who had served on the BHI Board since early 2013, is stepping down from her Board position after relocating to the West Coast
“The expansion of and continued diversity within the BHI Board, based upon new key industry and service provider representatives who are all deeply involved in life sciences, is a testament to the positive impact BHI has made on the Central Maryland biohealth community to date,” said Richard Bendis, BHI President & CEO.
“We look forward to the contributions from the new Board members representing these organizations. We’re also pleased to welcome a new Venable representative to the Board and that Mike Baader will continue to add value to the organization now that he is on the Greenspring Associates team,” said Douglas Liu, Chair, BHI Board of Directors, and Senior Vice President of Global Operations for Qiagen. “And, on behalf of the BHI staff and Board, I would also like to offer gratitude to Cynthia Collins for her service and contributions to the BHI Board over the last year and half.”
Managing Partner, Venable
Chuck Morton, repeatedly ranked as one of the top M&A lawyers in the country, Managing Partner of the Baltimore Office of Venable, Maryland’s largest law firm. He has a national practice, solving complex problems faced by lenders, investors, and entrepreneurs as they create, build, and buy or sell businesses. He routinely advises on mergers and acquisitions and financings, including every flavor of equity investment. He regularly acts on behalf of private equity groups. His practice focuses on life sciences and technology companies.
Chief Operating Officer/Chief Financial Officer & Board Member, miRecule, Inc.
Dave Lemus is an experienced C-Level executive (CEO-COO-CFO) and Non-Executive board member with extensive US & international business experience spanning over 20 years biotech in the biopharmaceutical industry, where he executed more than $3 billion in licensing, financing/capital markets and M&A transactions.
Additionally he also serves as a non-executive director on the boards of Sorrento Therapeutics (NASDAQ: SRNE), Silence Therapeutics plc (AIM: SLN), Celularity Inc., and the MIT Club Washington DC. Previously he was CEO of Sigma Tau Pharmaceuticals Inc., and prior to this, CFO of MorphoSys AG, where he launched Germany’s first biotechnology IPO in 1999, having come from Hoffmann La Roche in Basel.
He received his M.S. from the Massachusetts Institute of Technology, and B.S. from the University of Maryland, and is presently a C.P.A. in the state of Maryland.
Executive Chairman & Founder, Alexandria Real Estate Equities, Inc.
Joel S. Marcus is the Executive Chairman and Founder of Alexandria Real Estate Equities, Inc. (NYSE:ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in urban innovation clusters. Mr. Marcus co-founded Alexandria in 1994 as a garage startup with $19 million in Series A capital and, as CEO from March 1997 to April 2018, has led its growth into an S&P 500 company with an approximately $18 billion total market capitalization and significant market presence in leading AAA locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle Park. In, 1996, Mr. Marcus founded Alexandria Venture Investments, the company’s venture arm, which provides strategic capital to transformative life science and technology companies.